The initial focus will be on Zika and chikingunya, and will leverage iBio's antigen and antibody manufacturing capabilities for product prototype development.
The findings run counter to historical data and may provide fodder to reconsider current guideline recommendations on surveillance of colorectal cancer patients.
The test was previously cleared to run on the Sofia platform and can rapidly differentiate human IgM and IgG antibodies to Borrelia burgdorferi from serum and plasma specimens.
The researchers built a combination nucleic acid-antibody test for the disease using an approach they said could be generally useful for rapid test development.
